Identifying biomarkers of treatment efficacy in an efficient and accurate way is the key to a successful clinical trial. From biomarker discovery to the development of companion diagnostics, ACT Genomics is helping pharmaceutical companies shortening the distance between early target discovery and commercial launch.
Immunotherapy is a promising treatment option for cancer patients. However, the response rate remains low at approximately 20%. Therefore it is crucial to consider predictive biomarkers in patients’ treatment plans to identify those who will respond to immunotherapy.
Tumor Microenvironment Gene Expression Profiling
ACT TME is an RNA-based immune profiling assay that enables the characterization of tumor-immune microenvironment beyond traditional “immune-filtrated” or “non-immune-filtrated” classification, providing insights to facilitate immune-oncology drug development.
ACT TME Pathways
Covers TMB, MSI and Immune-related Genes
ACTOnco® sequences genes involved in immune response and antigen processing and presenting machinery. The mutation statuses of these genes will be considered when recommending immunotherapy. ACTOnco® covers TMB, MSI and immune-related genes to evaluate the use of immunotherapy.
Cancer is a multifactorial disease governed by large numbers of correlated genetic alterations that regulate the Hallmarks of Cancer. The Next Generation Sequencing (NGS) technology allows assessment of tumor genomics at the individual gene level, dissecting the pathophysiological pathways that lead to the multiple resistances model and therefore making it a potential approach for designing the right drugs for a cancer patient, with specific dosage, at a defined time interval.
Targeted panel sequencing is capable of providing clinically informative genetic alterations at high depth and high exon coverage. The number of genes included in a targeted panel can be categorized as follow: